There has been many exciting investments and advancements in the field, such as Atavistik Bio raising an additional $40 million to advance their small molecule therapeutics and Servier and Base4 […]

Optimize Safety & De-Risk Efficacy of Viral Vector-Based Gene Therapies The success of gene therapy hinges on overcoming the immunogenicity challenges of viral vectors. With more viral vector-based gene therapies […]

With Eli Lilly's acquisition of Mablink and Novartis' investment in Tagworks, both centering on their innovative linker and conjugation technologies - optimizing linker chemistry and diversifying conjugation technologies to increase stability and selectivity are becoming increasingly more […]